Author:
Pariente Alexandre,Arpurt Jean-Pierre,Rémy André-Jean,Rosa-Hézode Isabelle,Causse Xavier,Heluwaert Frédéric,Macaigne Gilles,Henrion Jean,Renou Christophe,Schnee Matthieu,Salloum Hatem,Hommel Séverine,Pilette Christophe,Arotcarena Ramuntxo,Barjonet Georges,Lison Hortensia,Bourhis François,Jouannaud Vincent,Pauwels Arnaud,Le eaBricquir Yann,Geagea Edmond,Condat Bertrand,Ripault Marie-Pierre,Zanditenas David,de Montigny-Lenhardt Stéphanie,Labadie Hélène,Tissot Bertrand,Maringe Eric,Cadranel Jean-François,Hagège Hervé,Lesgourgues Bruno
Reference21 articles.
1. Treatment of chronic hepatitis C with interferon alpha and ribavirin. Results in “real life”;Pariente;Gastroenterol Clin Biol,2003
2. Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in “true life”: a plea in favor of independent postmarketing evaluations;Pariente;Eur J Gastroenterol Hepatol,2010
3. Public-private partnership: targeting real-world data for hepatitis C direct-acting antivirals;Mishra;Gastroenterology,2017
4. Guidelines for the diagnosis of uncomplicated cirrhosis;Fontaine;Gastroenterol Clin Biol,2007
5. Common Terminology Criteria for Adverse events (CTCAE)V 4. 03;U.S. department of health and human services. National Institute of Health National Cancer Institute,2010